Neoprobe books $25 million loss in Q3
Dublin, Ohio-based Neoprobe has posted its 2009 third quarter results, showing a net loss of more than $25 million.
The company experienced net sales of $2.5 million for the 2009 third quarter, ending Sept. 30, a figure up from the $1.7 million posted in last year’s third quarter. Also, Neoprobe’s third quarter 2009 operating expenses were $2 million compared with $2.4 million for the third quarter of 2008.
Despite raking in net sales of $2.5 million, the biomedical company posted a net loss of $25 million in the 2009 third quarter, a figure substantially up from 2008’s third quarter net loss of $1.8 million. The company revealed that the net loss of $25 million included $16.2 million attributable to paying off debt.
The company experienced net sales of $2.5 million for the 2009 third quarter, ending Sept. 30, a figure up from the $1.7 million posted in last year’s third quarter. Also, Neoprobe’s third quarter 2009 operating expenses were $2 million compared with $2.4 million for the third quarter of 2008.
Despite raking in net sales of $2.5 million, the biomedical company posted a net loss of $25 million in the 2009 third quarter, a figure substantially up from 2008’s third quarter net loss of $1.8 million. The company revealed that the net loss of $25 million included $16.2 million attributable to paying off debt.